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Conclusions: A systematic reduction of air pockets within CTV occurs 
over treatment course. While these anatomical changes don’t affect 
so much the dosimetric outcome in term of OAR irradiation, a not 
negligible degradation of target coverage and dose homogeneity is 
pointed-out. In some cases this degradation couldn’t be clinically 
tolerable. If re-planning is performed on the first control CT the 
stability of dose distributions over the remaining treatment time 
improves.  
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Purpose/Objective: Proton therapy has the potential to deliver a 
superior distribution of radiation dose to the patient compared with 
photon therapy. On the other hand, proton treatments are more 
sensitive to setup variations and anatomical changes. In particular, a 
site where proton therapy could be highly beneficial is lung cancer. 
However, the anatomical changes in lung cancer provide a big 
challenge to deliver the planned dose. As part of the development of 
probabilistic planning systems, where knowledge about geometric 
uncertainties is taken into account during plan optimization, we are 
studying the effect of observed anatomical changes in lung cancer 
patients on scanned beam proton treatments. 
Materials and Methods: We selected three lung cancer patients with 
tumors close to the mediastinum that might be eligible for SBRT with 
protons, while they cannot be delivered with photons due to dose 
limiting constraints. For each patient we had the planning CT and five 
CBCT scans available. We used the research Pinnacle³ Intensity 
Modulated Proton Therapy (IMPT)/Spot Scanning treatment planning 
system (TPS)version 9.100 to create a proton plan for each patient 
using the original planning CT scan. These proton plans were kept very 
simple, consisting of two beams and optimized using the same 
objectives as the photon treatment plan. For every fraction, a CBCT 
was made just before the treatment. These scans represent the 
anatomy of the patient at that particular treatment day. We did not 
consider respiration motion, but used motion compensated CBCT scans 
to describe the 'baseline' anatomical changes. The CBCT scans cannot 
be directly used in the TPS to recalculate the dose as Hounsfield unit 
are not calibrated. Instead,the planning CT scan was deformed to 
every CBCT with in-house software, and dose was next recalculated 
using the original plan in Pinnacle³. The dose differences between the 
planned and delivered proton dose was evaluated 
Results:  
 
PTVmaxdose 
A(PTVmean = 
66.495Gy) 
B (PTVmean = 
66.685Gy) 
C (PTVmean = 
66.685Gy) 
difference 
(Gy) 
relative 
diff (%) 
difference 
(Gy) 
relative 
diff (%) 
difference 
(Gy) 
relative 
diff (%)  
scan1  23.40 -35.19 56.66 -84.91 29.85 -44.77 
scan2 23.84 -35.75 25.65 -38.46 46.50 -69.74 
scan3 26.56 -39.84 25.48 -38.21 44.63 -66.94 
scan4 23.46 -35.28 35.84 -53.75 36.81 -55.21 
scan5 22.35 -33.61 25.71 -38.55 28.26 -42.39 
mean 23.92 -35.93 33.87 -50.79 37.21 -55.81 
standard 
deviation 2.58 2.33 13.49 20.23 8.30 12.45 
 
(table caption: table 1 The maximum dose difference between the 
planningCT and the CBCT scans of the three patients inthe PTV) 
The results in table 1 show a remarkable underdosages in the planning 
treatment volume (PTV) coverage from 36% to 56%. 
Conclusions: Patient anatomy changes occuring during typical lung 
treatments, lead to significant under and overdosage, e.g. the PTV 
underdosages shown in this study. Based on this study, we can 
conclude that classical planning strategies applied for proton therapy 
are unsafe in the lung, and that more advanced planning strategies 
including knowledge of geometrical uncertainties need to be 
developed. 
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Purpose/Objective: To determine and assess the dosimetric 
difference between three emerging treatment modalities, which are 
intensity modulated proton therapy (IMPT), intensity modulated 
carbon ion beam therapy (IMIT) and rotational IMRT (VMAT) for two 
tumour sites where selective boosting of the tumour is applied.  
Materials and Methods: The planning study was retrospectively 
performed on each 10 patients with locally advanced head-and-neck 
(H&N) cancer and high-risk prostate cancer (PC). For each patient a 
VMAT plan was generated for the PTVinitial that included LN regions, 
delivering 50 GyE for H&N and 50.4 GyE for PC patients. Furthermore, 
3 separate boost plans (VMAT, IMPT and IMIT) were created to boost 
the PTVboost up to 70 GyE and 78 GyE for H&N and PC cases, 
respectively. Doses to the primary OARs i.e brainstem, myelon, larynx 
and parotid glands were assessed for H&N cases. Additionally, various 
OARs whose sparing can be associated with improved quality of life 
after treatment were delineated. For PC cases doses to bladder, 
rectum as well as femoral heads were analyzed. In order to sum up 
the total doses, dose matrices of the initial VMAT plans and the 
respective boost plans were mapped together. 
Results: H&N cases: The targets goals were easily met, with higher 
median dose found for VMAT+VMAT compared to VMAT+IMPT and 
VMAT+IMIT (58.2 (4.9) GyE, 53.8 (3.9) GyE, 53.4 (1.3) GyE, 
respectively). All the primary OARs were spared the least by the 
VMAT+VMAT method. Mean doses for VMAT+IMPT and VMAT+IMIT was 
approximately 3 GyE lower for contralateral parotis and 1.5 GyE lower 
for larynx comparing to VMAT+VMAT results. Similarly, D2GyE was on 
average 2 GyE lower for myleon and 2.6 GyE lower for brainstem. 
Moreover, no significant difference was detected between VMAT+IMPT 
and VMAT+IMIT. Considering additional OARs a big improvement was 
found for the VMAT+IMIT method especially in sparing the ipsilateral 
cochlea, middle ear, masticator space as well as the base of tongue 
and soft palate. 
PC cases: In terms of target coverage all 3 modalities reached the 
prescribed goals, with slightly higher average median dose to PTVinital 
for the VMAT+VMAT method, 52.3 (3.2) GyE compared to VMAT+IMPT 
and VMAT+IMIT (51.1 (1.7) GyE and 51.2 (1.4) GyE respectively). 
Similarly, V95% was found to be higher for PTVinitial (VMAT+VMAT = 99.1% 
